The earnings call presented a mixed picture. While there were significant achievements in terms of new client acquisitions and strategic partnerships, the quarter's financial performance was below expectations, with notable declines in ART cycles and gross margin. The client retention rate remains high, but the loss of a significant client and adjustments in guidance indicate challenges. Overall, the company is making strategic moves to strengthen its position, but variability in member activity remains a concern.
Company Guidance
During the third quarter earnings call for Progyny, Inc., various metrics and guidance for the upcoming months were discussed. The company reported a third quarter revenue of $286.6 million, reflecting a 2% growth over the previous year, primarily driven by an increase in clients and covered lives. Despite this growth, third-quarter results fell below expectations due to unanticipated changes in member activity, particularly in consumption patterns, which resulted in a reported ART cycle count of approximately 14,900, declining by just under 1% from the previous year. The utilization rate remained stable at 0.47%, consistent with historical patterns. Progyny successfully added 1.1 million new lives from over 80 new client commitments for the upcoming year, maintaining a strong position in a large and growing market. However, the company also noted a slight decrease in gross margin to 20.7% compared to the prior year, attributed to increased investments in care management services. Looking ahead, Progyny provided a revenue guidance range of $266.2 million to $281.2 million for the fourth quarter, translating to a full-year forecast between $1.135 billion and $1.150 billion. The company also expects adjusted EBITDA for the fourth quarter to be between $37.8 million and $42.8 million. Despite variable trends observed in 2024, Progyny remains confident in its strategic positioning and anticipates continued growth and profitability into 2025.
Strong Selling Season
1.1 million new lives added from over 80 new client commitments for the fourth straight year. Strong interest in new products contributed to success.
Client Retention and Upsell
99% client retention with approximately 30% of clients increasing their program in some way in 2025.
Strategic Partnerships
Added first national health plan and another large regional health plan, expanding channel partner relationships.
Cash Flow and Share Buyback
Generated $127 million of operating cash flow over the first 9 months, with $61.4 million spent on share buybacks in Q3.
---
Progyny (PGNY) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PGNY Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2024
$17.18
$13.90
-19.09%
Aug 06, 2024
$25.74
$20.85
-19.00%
May 09, 2024
$32.50
$27.53
-15.29%
Feb 27, 2024
$40.79
$34.65
-15.05%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Progyny, Inc. (PGNY) report earnings?
Progyny, Inc. (PGNY) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Progyny, Inc. (PGNY) earnings time?
Progyny, Inc. (PGNY) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.